Experimental Drug Helps Fight Aggressive Breast Cancer:
WEDNESDAY, Jan. 5 (HealthDay News) -- Researchers have taken
another step in the hunt to find a treatment for an aggressive,
likely-to-recur form of breast cancer.
In a study published in the Jan. 5 online edition of the
New England Journal of Medicine, the experimental drug iniparib not only shrank tumors and increased the time they took to progress, but also surprised researchers by prolonging survival in women with what's known as triple-negative breast cancer.
This type of breast cancer lacks receptors for estrogen and
progesterone and doesn't have large quantities of HER-2/neu
protein, which the most successful cancer therapies target. This
means that many currently available drugs simply won't affect
"We were surprised [at the results] because triple-negative breast cancer is very difficult to treat," said study lead author Dr. Joyce O'Shaughnessy.
"The big, big surprise was survival," added O'Shaughnessy, who nevertheless stressed that the trial was small and preliminary.
The findings were enough to generate the interest of Dr. Lisa A.
Carey, the co-author of an accompanying editorial.
"It is early, but it's really exciting because it's a new class of drugs. It isn't that often that we have a completely new approach to treating cancer," said Carey, medical director of the University of North Carolina Breast Center in Chapel Hill. "This is a new book. We've just opened it up."
Iniparib inhibits a pathway that helps repair DNA; researchers
call it the poly(ADP-ribose) polymerase (PARP) pathway. If this
chain is interrupted, cancer cells don't have the necessary tools
to repair themselves.
"[PARP inhibitors] work by preventing the cells from repairing damage to their DNA," Carey explained.
A similar drug, in fact, has shown benefit in patients with BRCA
1 or BRCA 2 mutations predisposing them to breast and ovarian
In this study, 123 patients with triple-negative breast cancer
were randomized to receive a commonly used, well-tolerated
chemotherapy regimen (gemcitabine and carboplatin) or to receive
chemo plus iniparib.
More than one-half of the women responded to the combination
treatment (meaning the tumor volume decreased) versus only about
one-third of those receiving chemo alone.
Women receiving iniparib plus chemo lived an average of 12.3
months compared to just 7.7 months in the chemo-alone group. This
may not seen like very long in either group, but for this serious a
cancer, it is impressive, the researchers noted.
This was a phase 2 trial. O'Shaughnessy, who is co-director of
breast cancer research at Baylor-Sammons Cancer Center, US
Oncology, and Texas Oncology in Dallas, said the results of a
larger (about 500 patients) phase 3 trial should be available
within one to three months.
"The whole field is still preliminary and we have to be careful not to overhype the results [as] we're waiting on the results of the phase 3 trial," she said. "Phase 2 was quite positive, but we really don't know if this is going to end up benefiting patients until we get to phase 3."
In her editorial accompanying the study, Carey agreed. "Both
excitement and caution are appropriate in interpreting the trial,"
she wrote. "Some clear drawbacks should be noted." Among them, she
said, were the small size of the study group, "imbalances at
baseline" favoring the iniparib group, and the "unconventional"
chemotherapy regimen. But caveats notwithstanding, she concluded,
the results may herald improved therapy "for an underserved
subgroup of patients with breast cancer."
O'Shaughnessy added that the drug was "extremely well tolerated
[by patients]. It didn't seem to add any appreciable toxicity to
In the meantime, she pointed out, a woman walking through a
clinic door who is diagnosed with triple-negative breast cancer
shouldn't panic. "If it's only in the breast or lymph nodes, we
cure most triple-negative cancers. But when it recurs and becomes
metastatic, it's very difficult to treat," she explained.
The study was funded by BiPar Sciences, a subsidiary of
Sanofi-Aventis which makes the drug.
The U.S. National Cancer Institute has more on
Copyright © 2011
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.